In an effort to provide accurate and easily accessible information about the ongoing COVID-19 pandemic, the Multiple Sclerosis Association of America (MSAA) and Wondros are proud to announce the creation of the COVID-19 and MS Pathfinder online tool, available on MSAA’s website at https://mymsaa.org/covid-19-and-ms-pathfinder/. The COVID-19 and MS Pathfinder tool allows members of the multiple […]

The Multiple Sclerosis Association of America advocates equally for all members of the MS community, and supports all peaceful efforts aimed at erasing the inequalities that exist between people of different races, religions, gender, and economic backgrounds, as well as those with disabilities. MSAA recognizes the inequities and overwhelming pain associated with discrimination and senseless acts of injustice.

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD The commercial launch and availability of Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS) was officially announced today. Initially approved by the United States Food and Drug Administration (FDA) on March 25, 2020, the makers of Zeposia, Bristol Myers Squibb, […]

Challenges presented by the COVID-19 pandemic can be even more stressful and overwhelming for people living with chronic illnesses. As a trusted resource for the multiple sclerosis (MS) community, the Multiple Sclerosis Association of America (MSAA) is committed to providing accurate, up-to-date information, and resources during this time. Webinars about COVID-19 and Multiple Sclerosis Streamed […]

On April 30, 2020, Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced the United States Food and Drug Administration (FDA) approval of Bafiertam™ (monomethyl fumarate) delayed-release oral capsules to treat relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Banner has not yet announced when the medication will be available to the MS community.

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD Overview On March 26, 2020, Bristol Myers Squibb announced that the United States Food and Drug Administration (FDA) approved Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS […]

The “coronavirus disease 2019” (COVID-19) is a potentially serious respiratory disease that was first reported in December 2019 in China. As of early March 2020, the illness had made its way to almost 70 locations, including the United States, and has affected more than 90,000 individuals worldwide. Please be aware that these figures are expected to increase on a weekly or even a daily basis.

The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. For this year’s campaign, MSAA is focusing on The Mind, Body, and MS Connection, addressing the integration of physical and emotional wellness strategies to improve MS symptom management and overall quality of life. MSAA invites the MS community to participate […]

The Multiple Sclerosis Association of America (MSAA), founded in 1970, is proud to recognize its 50th Anniversary in 2020 as a nonprofit organization dedicated to supporting the multiple sclerosis community and Improving Lives Today through vital services and support. MSAA would like to share several initiatives and events dedicated to commemorating this important milestone: To […]

To live with multiple sclerosis (MS) is to cope with the challenges it presents and to look forward to the promise of ongoing progress in understanding and managing the condition. This edition of “What’s New in MS Research” reflects that mix of obstacles and opportunities.